Overview

Charles River’s experience with oncology drug discovery spans all phases, from target identification to IND studies. Utilizing the most effective combination of tools available to identify promising compounds, we work with our partners to design studies by selecting from amongst a broad range of well-characterized xenograft, patient-derived xenograft (PDX) and syngeneic tumor models. Combining those models with appropriate biomarkers, including flow cytometry and imaging, allows our partners to choose the most appropriate study design and screening method to identify promising compounds and optimize lead candidates.